-
Independent Peer-Reviewed Study Validates Therapeutic Mode of Action of Cardior’s First-in-Class Heart Failure Program
Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, announced today that a recent peer-reviewed study confirms the therapeutic mode of action of Cardior´s lead program CDR132L. CDR132L blocks the naturally occurring microRNA miR-132 which, if overexpressed, is a key driver of heart failure. The study was published in Frontiers in Cardiovascular Medicine (doi:10.3389/fcvm.2021.592362) by an international group of scientists from Stanford University School of Medicine (USA), the University Medical Center Utrecht (The Netherlands) and Shanghai University (China).[1] In their publication, Lei et al. investigate the molecular mechanisms of two microRNAs, miR-132 and miR-212, in modulating cardiomyocyte…
-
Cardior Pharmaceuticals‘ Lead Compound Demonstrates Improvement of Heart Function in Chronic Heart Failure Model
Safety and efficacy of CDR132L established in an in vivo model of chronic post-MI heart failure Study by international research team published in European Heart Journal Broad treatment potential for chronic heart failure Cardior Pharmaceuticals GmbH, a clinical-stage biotech company, focused on the development of noncoding RNA (ncRNA) therapeutics for patients with cardiovascular diseases, today announced a publication in the European Heart Journal (doi:10.1093/eurheartj/ehaa791) demonstrating that repeated treatment with its lead compound CDR132L is safe, improves cardiac function and reduces both ventricular as well as left atrial volumes in chronic heart failure. The results were obtained in a clinically relevant, post-myocardial infarction large animal model. The research was conducted by…
-
Cardior Pharmaceuticals Demonstrates Reversal of Cardiac Hypertrophy by H19 Gene Therapy
Administration of AAV9 expressing H19 attenuates cardiac hypertrophy in vivo and prevents progression to heart failure Details on novel mechanism of action published in peer-reviewed study in the European Heart Journal Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of noncoding RNA (ncRNA) therapeutics for patients with cardiovascular diseases, today announced the results of extensive in vitro and in vivo studies demonstrating the therapeutic potential of H19 gene therapy to combat cardiac hypertrophy and heart failure. Results were published in the European Heart Journal (doi: 10.1093/eurheartj/ehaa519) [1]. Research was performed by an international team of researchers from Germany, Austria, and the U.S. H19 is an IP-protected target…
